Sanofi Catching Up To Market Growth Rates As Q3 Sales Rise Double Digits
Sanofi Consumer Healthcare's second successive quarter of growth means the business is now growing almost as fast as the global OTC market. Business head Julie Van Ongevalle has won praise from the French group's CEO Paul Hudson for driving a "quite extraordinary" transformation.
You may also be interested in...
Sanofi will look to offload around 150 OTC brands as part of a radical overhaul of its Consumer Healthcare operation. The new head of the business Julie Van Ongevalle has unveiled a wide-ranging turnaround plan with the goal of transforming Sanofi into the OTC market leader.
Sanofi eyes $1bn top line growth from OTC switches of ED drug Cialis and flu drug Tamiflu after they launch by 2026, says CEO Paul Hudson. Like switch consultants, though, he acknowledges the high bar for approval moving additional Rx ingredients to OTC.
UK-based Alliance Pharma saw sales rise double-digits in 2021, with acquisitions bolstering the performance of its established brands. Going into 2022, the company says it is in a strong position to pursue M&A in the consumer health space.